Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$7.20
+1.6%
$6.07
$4.92
$9.30
$23.61M1.0323,321 shs38,811 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$1.92
-1.8%
$2.14
$1.55
$5.59
$13.48M0.41493,860 shs13,560 shs
Flora Growth Corp. stock logo
FLGC
Flora Growth
$0.74
-4.3%
$0.62
$0.42
$2.11
$16.76M2.04275,152 shs122,584 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.17
-2.5%
$1.25
$0.70
$2.44
$13.54M0.65160,473 shs13,897 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.00%+7.07%+27.57%+24.91%-9.84%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%+4.92%-4.00%-19.67%-57.05%
Flora Growth Corp. stock logo
FLGC
Flora Growth
0.00%+16.00%+12.48%+19.68%-33.71%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00%-6.40%-19.86%+61.33%-42.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
2.1005 of 5 stars
3.64.00.00.01.00.00.6
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
3.3398 of 5 stars
3.55.00.00.03.01.70.6
Flora Growth Corp. stock logo
FLGC
Flora Growth
2.7016 of 5 stars
3.33.00.00.03.10.81.3
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.7946 of 5 stars
0.05.00.00.03.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.20
Buy$33.00358.65% Upside
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
3.00
Buy$21.00993.75% Upside
Flora Growth Corp. stock logo
FLGC
Flora Growth
2.50
Moderate Buy$4.00438.79% Upside
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ARTL, TXMD, FLGC, and EDSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/6/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
4/28/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/2/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A$4.12 per shareN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.18 per shareN/A
Flora Growth Corp. stock logo
FLGC
Flora Growth
$53.26M0.31N/AN/A$0.78 per share0.95
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.84M7.36N/AN/A$2.77 per share0.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$9.29M-$2.99N/AN/AN/AN/A-104.59%-94.06%8/12/2025 (Estimated)
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$6.17M-$1.59N/AN/AN/AN/A-233.69%-124.14%8/8/2025 (Estimated)
Flora Growth Corp. stock logo
FLGC
Flora Growth
-$57.04M-$0.98N/AN/AN/A-30.99%-268.17%-57.51%8/11/2025 (Estimated)
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/A-207.77%-14.08%-9.61%8/11/2025 (Estimated)

Latest ARTL, TXMD, FLGC, and EDSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q2 2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.30-$0.30N/A-$0.30N/AN/A
5/13/2025Q1 2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$0.78-$4.32-$3.54-$0.72N/AN/A
5/13/2025Q1 2025
Flora Growth Corp. stock logo
FLGC
Flora Growth
-$0.01-$0.04-$0.03-$0.04$14.79 million$11.79 million
5/13/2025Q1 2025
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A-$0.06N/A-$0.06N/A$0.39 million
3/24/2025Q4 2024
Flora Growth Corp. stock logo
FLGC
Flora Growth
-$0.11-$0.42-$0.31-$0.45$13.55 million$13.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
Flora Growth Corp. stock logo
FLGC
Flora Growth
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
7.15
7.15
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
1.09
0.91
Flora Growth Corp. stock logo
FLGC
Flora Growth
0.43
1.02
0.64
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
2.03
2.03

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
Flora Growth Corp. stock logo
FLGC
Flora Growth
36.01%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.83%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
22.60%
Flora Growth Corp. stock logo
FLGC
Flora Growth
12.56%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
53.28 million3.20 millionNot Optionable
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
207.02 million2.60 millionNot Optionable
Flora Growth Corp. stock logo
FLGC
Flora Growth
28022.57 million12.55 millionNot Optionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
42011.57 million11.27 millionOptionable

Recent News About These Companies

TherapeuticsMD Shifts Focus with Lower Q3 Losses
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$7.20 +0.11 (+1.56%)
Closing price 06/13/2025 03:58 PM Eastern
Extended Trading
$6.85 -0.34 (-4.74%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$1.92 -0.04 (-1.79%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.94 +0.02 (+1.04%)
As of 06/13/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Flora Growth stock logo

Flora Growth NASDAQ:FLGC

$0.74 -0.03 (-4.33%)
Closing price 06/13/2025 03:56 PM Eastern
Extended Trading
$0.73 -0.01 (-1.67%)
As of 06/13/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

TherapeuticsMD stock logo

TherapeuticsMD NASDAQ:TXMD

$1.17 -0.03 (-2.50%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-0.85%)
As of 06/13/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.